This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
 
Tesla's Tune-up: Legal Brawls, Delivering the Model X and Earnings

The stock is still up 50 percent so far this year, and Tesla is taking automotive jobs to more welcoming climates.

Apple, Gannett & GNC Earnings, Plus Jim Cramer's Tech Pick

Monday kicks off a big earnings day from Gannett, which still plans to split itself, as well as GNC Holdings.

What to Watch on Wall Street for the Week of Oct. 20, 2014

In the week ahead, we have some heavy hitters coming up in the midst of earnings season, including Apple, Amazon and Ford.

U.S. Malls Will Survive Scares Like Ebola, Online Shopping Growth

The Mall at University Town Center in Sarasota, Florida has just opened its doors.

Penney Names New Chief, HBO Streams Ahead & Chrysler Comes Back

J.C. Penney ended its yearlong CEO search this week, naming retail industry veteran Marvin Ellison to officially replace interim CEO Myron Ullman.

Real Money Previews

Look Down!; Jump of a Lifetime; Not for the Faint of Heart: Best of Kass

In highlights from his trading diary of the past week, Doug Kass writes about how investors aren't looking in the right direction and frustration with such a volatile market.

We May Have an Investable Bottom; Smoke Always Clears: Jim Cramer's Best Blogs

Catch up on Jim Cramer's thinking over the last week about the signals that are saying it may be time to invest and the near-term and the longer-term outlooks.

Stock Market on Emotional Roller Coaster May Be Turning Optimistic

When markets hop on an emotional roller coaster, expect anxiety, denial, fear, desperation, panic and capitulation.

Mad Money Recap

'Mad Money' Lightning Round: Lots of Ways to Win With Molson Coors

Cramer is avoiding SeaDrill and Silicon Graphics but likes Gilead and Mettler-Toledo.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to find the stocks he and Stephanie Link think could be HUGE winners. Click here to see them for FREE.

Stock Ideas

How to Trade the Market's Most-Active Stocks

Here's how to trade some of the most active stocks on the market today.

4 Big Stocks on Traders' Radars

Here's how to trade some of the most active stocks on the market today.

5 Dividend Stocks Ready to Give Investors a Raise

Dividends still matter in this market, and these five could be about to get bigger.

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

2 Oversold Stocks Under $10 Ready to Bounce Higher

Oversold can always get more oversold, but it's also an area from which a stock can experience a powerful bounce higher.

MainStreet

You Can Ruin Your Retirement If You're Living In This State

Where you spend your golden years has a big influence on the happiness you experience in retirement.

Why Geopolitical Risk Could Actually Be Good For Your Portfolio

The turmoil in the world isn't all bad news.

Am I Covered By My Insurance If I Get Ebola? Practicality Amid Panic

With all the frenzy surrounding the latest developments about Ebola, some consumers may be wondering if their health insurance plan covers rare diseases and outbreaks.

How to Get the Best Deal on a Smartphone Before 2018 Price Drop

You don't have to wait to get a big discount on a new smartphone. They're available now if you know where to look.

Can a Bar Truly Charge Anything When You Forget Your Credit Card?

Charges for cards left overnight may be legal, but that doesn't mean you can't have cause to dispute one.

Biotech

First Detailed Look at Celgene Crohn's Disease Pill Impresses

As a pill, Celgene's GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Brainstorm CEO Offers Investors a Frank Outlook for ALS Therapy

Given the usual hype surrounding small-cap biotechs, Brainstorm CEO Tony Fiorino is refreshingly candid about the company's chances of developing a stem-cell treatment to counter ALS symptoms.

Beyond Wall St.

Deal News

IBM Reportedly Pays $1.3 Billion to GlobalFoundries to Take Failing Chip Unit

IBM looks to be plugging a $1.5 billion drain on its earnings with a semiconductor unit sale to Abu Dhabi-owned GlobalFoundries.

Every Hedge Fund in America Wants its 2-Cents on Family Dollar Deal

Almost every large activist hedge fund may get their 15-minutes of attention by the time Family Dollar’s takeover saga ends.

KKR Looks to Get More Bang for Its Buck in Strategy Shift

KKR, one of the inventors of modern-day private equity, is trying to move in a new direction by investing larger sums of its own money into buyout deals.

TheStreetTV
Spin Space

Jim Cramer

We May Have an Investable Bottom; Smoke Always Clears: Jim Cramer's Best Blogs

Catch up on Jim Cramer's thinking over the last week about the signals that are saying it may be time to invest and the near-term and the longer-term outlooks.

Herb Greenberg

Greenberg: Hedge Funds Should Really Short Not Take Lazy Route

When will real short-selling come back into vogue?

Stephanie Link

Stephanie Link: You Can Still Find Value in this Pullback

Action Alerts PLUS has been buying into it.

Chris Ciaccia

IBM Plunges Following Huge Third-Quarter Earnings Miss and Asset Sale

IBM shares plunge after the company badly misses third-quarter earnings estimates and after it paid GlobalFoundries $1.5 billion to take its money-losing semiconductor unit off its...

Adam Feuerstein

First Detailed Look at Celgene Crohn's Disease Pill Impresses

As a pill, Celgene's GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.

Dan Freed

Why Goldman's Earnings Beat Matters More Than in Previous Quarters

Unlike in previous quarters, Goldman's strong third-quarter earnings performance was powered by businesses that are part of the company's future.

Ted Reed

Delta to Wall Street: Don't Tell Us How to Run Our Airline

Delta is widely seen as the leading U.S. airline, yet some Wall Street analysts have decided it is adding too much capacity, breaking the mold of 'capacity discipline.'

Leon Lazaroff

Seven Totally Cool, New-Techie Products You Need to See

A new online network for investors to a tiny WI-fi hotspot and an tablet that the whole family can watch at the same time.

Submit an article to us!
DOW 16,273.76 -106.65 -0.65%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs